SG11202106990PA - BISPECIFIC ANTIBODY BINDING TO TfR - Google Patents
BISPECIFIC ANTIBODY BINDING TO TfRInfo
- Publication number
- SG11202106990PA SG11202106990PA SG11202106990PA SG11202106990PA SG11202106990PA SG 11202106990P A SG11202106990P A SG 11202106990PA SG 11202106990P A SG11202106990P A SG 11202106990PA SG 11202106990P A SG11202106990P A SG 11202106990PA SG 11202106990P A SG11202106990P A SG 11202106990PA
- Authority
- SG
- Singapore
- Prior art keywords
- tfr
- bispecific antibody
- antibody binding
- binding
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018248334 | 2018-12-28 | ||
| PCT/JP2019/051594 WO2020138487A1 (ja) | 2018-12-28 | 2019-12-27 | ＴｆＲに結合するバイスペシフィック抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106990PA true SG11202106990PA (en) | 2021-07-29 |
Family
ID=71125764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106990PA SG11202106990PA (en) | 2018-12-28 | 2019-12-27 | BISPECIFIC ANTIBODY BINDING TO TfR |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12258413B2 (https=) |
| EP (1) | EP3903816A4 (https=) |
| JP (2) | JP7506607B2 (https=) |
| KR (1) | KR20210108961A (https=) |
| CN (1) | CN113226371B (https=) |
| AU (1) | AU2019413278B2 (https=) |
| BR (1) | BR112021012569A2 (https=) |
| CA (1) | CA3125316A1 (https=) |
| MX (1) | MX2021007797A (https=) |
| MY (1) | MY210422A (https=) |
| SG (1) | SG11202106990PA (https=) |
| TW (2) | TWI873112B (https=) |
| WO (1) | WO2020138487A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| EP4688846A1 (en) * | 2023-03-24 | 2026-02-11 | BioArctic AB | Antibody binding to the protease-like domain of the human transferrin receptor htfr1 |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025090898A1 (en) * | 2023-10-26 | 2025-05-01 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof cross reference to related applications |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US570561A (en) | 1896-11-03 | S peters co | ||
| US2808035A (en) | 1953-04-23 | 1957-10-01 | Riley Stoker Corp | Burning wet materials |
| JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
| JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
| WO1985003934A1 (fr) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Proteine modifiee chimiquement et son procede de preparation |
| JPS60221091A (ja) | 1983-12-21 | 1985-11-05 | Kyowa Hakko Kogyo Co Ltd | 新規プロモ−タ− |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| JP2564268B2 (ja) | 1985-08-28 | 1996-12-18 | 協和醗酵工業株式会社 | 融合抗原ポリペプチド |
| ZA872705B (en) | 1986-04-22 | 1987-10-05 | Immunex Corporation | Human g-csf protein expression |
| JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
| JP3131322B2 (ja) | 1991-12-17 | 2001-01-31 | 協和醗酵工業株式会社 | 新規α２→３シアリルトランスフェラーゼ |
| US6042828A (en) | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
| SG49117A1 (en) | 1993-03-29 | 1998-05-18 | Kyowa Hakko Kogyo Kk | Alfa -1, 3-fucosyltransferase |
| US5705614A (en) | 1993-04-09 | 1998-01-06 | Chiron Corporation | Methods of producing antigen forks |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| EP2990420B1 (en) * | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| KR100919593B1 (ko) | 2000-06-29 | 2009-09-29 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물 |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| WO2003033538A1 (en) | 2001-10-15 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Anti-hla-dr antibody |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2009131239A1 (ja) | 2008-04-25 | 2009-10-29 | Kyowa Hakko Kirin Co Ltd | 安定な多価抗体 |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| KR20120024763A (ko) * | 2009-05-15 | 2012-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항ａｘｌ 항체 |
| BRPI1010759B1 (pt) | 2009-06-11 | 2019-07-16 | Inter-University Research Institute Corporation Research Organization Of Information And Systems | Método para produzir uma proteína de interesse ou para obter uma suspensão de células de mamíferos capaz de produzir uma proteína de interesse, bem como vetor de expressão de proteína |
| WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| AR084020A1 (es) | 2010-11-30 | 2013-04-17 | Genentech Inc | Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos |
| CN105968209B (zh) | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| US9598496B2 (en) | 2011-05-09 | 2017-03-21 | Perseus Proteomics Inc. | Antibody capable of specifically recognizing transferrin receptor |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| MX361875B (es) | 2012-03-14 | 2018-12-18 | Regeneron Pharma | Moléculas de unión de antígeno multiespecifícas y usos de las mismas. |
| AU2013266611B2 (en) | 2012-05-21 | 2016-08-11 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| WO2014189973A2 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| CN104211814A (zh) | 2013-05-29 | 2014-12-17 | 三星电子株式会社 | 用于消耗靶膜蛋白的组合物 |
| TWI853985B (zh) * | 2013-12-04 | 2024-09-01 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
| SG11201608253XA (en) * | 2014-04-04 | 2016-10-28 | Kyowa Hakko Kirin Co Ltd | Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity |
| EP3221362B1 (en) * | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| EP3221361B1 (en) * | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| SG11201705632UA (en) * | 2015-01-08 | 2017-08-30 | Kyowa Hakko Kirin Co Ltd | Bispecific antibody binding to trailr2 and psma |
| MX391086B (es) * | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| CA2992262A1 (en) * | 2015-07-15 | 2017-01-19 | Kyowa Hakko Kirin Co., Ltd. | Antibody which specifically binds to human crth2 |
| KR20190005944A (ko) | 2016-05-09 | 2019-01-16 | 애넥슨, 인코포레이티드 | 척수성 근위축 치료용 조성물 및 방법 |
| KR102156626B1 (ko) | 2018-07-16 | 2020-09-17 | 주식회사 셀바스에이아이 | 운동 처방 정보를 제공하는 서버 및 컴퓨터 프로그램 |
-
2019
- 2019-12-27 JP JP2020562545A patent/JP7506607B2/ja active Active
- 2019-12-27 BR BR112021012569-8A patent/BR112021012569A2/pt unknown
- 2019-12-27 TW TW108148133A patent/TWI873112B/zh active
- 2019-12-27 EP EP19901837.5A patent/EP3903816A4/en active Pending
- 2019-12-27 US US17/418,447 patent/US12258413B2/en active Active
- 2019-12-27 CA CA3125316A patent/CA3125316A1/en active Pending
- 2019-12-27 MX MX2021007797A patent/MX2021007797A/es unknown
- 2019-12-27 SG SG11202106990PA patent/SG11202106990PA/en unknown
- 2019-12-27 TW TW114101537A patent/TWI907249B/zh active
- 2019-12-27 CN CN201980086662.6A patent/CN113226371B/zh active Active
- 2019-12-27 KR KR1020217019406A patent/KR20210108961A/ko active Pending
- 2019-12-27 WO PCT/JP2019/051594 patent/WO2020138487A1/ja not_active Ceased
- 2019-12-27 MY MYPI2021003612A patent/MY210422A/en unknown
- 2019-12-27 AU AU2019413278A patent/AU2019413278B2/en active Active
-
2024
- 2024-06-14 JP JP2024096802A patent/JP2024119984A/ja active Pending
-
2025
- 2025-02-19 US US19/057,265 patent/US20250250352A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220017635A1 (en) | 2022-01-20 |
| BR112021012569A2 (pt) | 2021-09-14 |
| JPWO2020138487A1 (ja) | 2021-11-11 |
| AU2019413278B2 (en) | 2026-04-09 |
| AU2019413278A1 (en) | 2021-07-15 |
| WO2020138487A1 (ja) | 2020-07-02 |
| JP7506607B2 (ja) | 2024-06-26 |
| KR20210108961A (ko) | 2021-09-03 |
| US20250250352A1 (en) | 2025-08-07 |
| NZ777568A (en) | 2025-05-02 |
| TW202517296A (zh) | 2025-05-01 |
| EP3903816A1 (en) | 2021-11-03 |
| CA3125316A1 (en) | 2020-07-02 |
| MX2021007797A (es) | 2021-10-26 |
| JP2024119984A (ja) | 2024-09-03 |
| EP3903816A4 (en) | 2022-09-07 |
| US12258413B2 (en) | 2025-03-25 |
| CN113226371B (zh) | 2025-05-30 |
| TWI907249B (zh) | 2025-12-01 |
| TWI873112B (zh) | 2025-02-21 |
| CN113226371A (zh) | 2021-08-06 |
| MY210422A (en) | 2025-09-22 |
| TW202039581A (zh) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276537A (en) | Antibodies bind to GPRC5D | |
| IL287613A (en) | Antibodies that bind gprc5d | |
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| SG10202105788SA (en) | Antibodies binding to cd3 | |
| IL268527A (en) | Bispecific antibodies bind PD1 and LAG3 specifically | |
| ZA202203250B (en) | Cd3 binding antibodies | |
| SG11202100096XA (en) | Antibodies binding to ilt4 | |
| ZA202004908B (en) | Bispecific antibody | |
| SG11202106990PA (en) | BISPECIFIC ANTIBODY BINDING TO TfR | |
| IL274121A (en) | Bispecific antibodies that bind ALK-1 and BMPR-2 | |
| LT3115376T (lt) | Antikūnai, kurie jungiasi su žmogaus cd3 | |
| DK3122781T3 (da) | Bispecifikke antistoffer, der binder til cd38 og cd3 | |
| GB201710838D0 (en) | Bispecific antibodies | |
| IL282590A (en) | Heavy chain antibodies that bind to CD38 | |
| IL269394A (en) | Antibodies bind to STEAP-1 | |
| IL271832A (en) | Bispecific antibodies against PD1 and against TIM3 | |
| ZA202104356B (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| IL286757A (en) | Antibodies in specific | |
| IL274676A (en) | The bispecific antigen binding composition | |
| IL269577B (en) | Bispecific antibodies anti–pd–l1–anti–tim–3 | |
| IL286918A (en) | Bispecific antibody | |
| ZA202206008B (en) | Bispecific anti-ccl2 antibodies | |
| IL290050A (en) | Bispecific antibody | |
| PT3802598T (pt) | Proteínas de ligação dll3/cd3 para tratamento de cancro |